Skip to main content

Blog

Original Source

By Sidley Austin LLP Visit the blog

57 published works

  1. Original Source

    Strictly Enforcing Rule 9(b), Second Circuit Affirms Dismissal of FCA Claim Based on Allegedly Defective Medical Devices

    By Jaime L.M. Jones, Scott D. Stein, Joseph R. LoCascio, Anna M. Schmitt

    The Second Circuit affirmed dismissal of an FCA qui tam based on allegedly faulty medical devices, an area marked for particular FCA scrutiny by the DOJ-HHS FCA Working Group, as…

  2. Original Source

    Court Grants Motion to Dismiss FCA Claim for Failure Adequately to Plead Scienter

    By Jaime L.M. Jones, Scott D. Stein, Joseph R. LoCascio, Hannah Zobair

    Recently a court took the rare step of granting a motion to dismiss a qui tam suit because the relator’s vague and conclusory scienter allegations failed to satisfy Rules 8…

  3. Original Source

    TX AG’s Office Continues Aggressive Enforcement Against Healthcare Entities Operating in Texas

    By Jaime L.M. Jones, Kenneth G. Coffin

    In just the last week, the Texas Attorney General’s Office (“TX AG’s Office”) filed three actions against healthcare providers and entities, continuing an increasingly robust and aggressive enforcement regime that…

  4. Original Source

    DAAG Brenna Jenny Warns Heightened FCA Enforcement Is “The New Normal,” Addresses Enforcement Priorities and Policies

    By Jaime L.M. Jones, Kristin Graham Koehler, Hannah Zobair, Anna M. Schmitt

    During her keynote speech at the Federal Bar Association’s Qui Tam Conference, Brenna Jenny,  Deputy Assistant Attorney General for the Commercial Litigation Branch, stated that robust FCA enforcement is “the…

  5. Original Source

    DAAG Jenny Reinforces Commitment to FCA Enforcement Premised on Discrimination

    By Jaime L.M. Jones, Kristin Graham Koehler, Joseph R. LoCascio

    At the Federal Bar Association’s Qui Tam Conference, Brenna Jenny, the Deputy Assistant Attorney General of DOJ’s Commercial Litigation Branch, offered the most detailed description yet of the Trump Administration’s…

  6. Original Source

    DOJ Attorneys Underscore Heightened Focus on Trade Fraud During the Annual Qui Tam Conference

    By Jaime L.M. Jones, Kristin Graham Koehler, Craig Francis Dukin, Ted Murphy, Justin R. Becker, Kenneth G. Coffin

    Speaking as part of a panel at the Federal Bar Association’s annual Qui Tam Conference today, a Senior Trial Counsel at the Department of Justice (DOJ), Christelle Klovers, emphasized the…

  7. Original Source

    FY 2025 FCA Settlements and Judgments Statistics Show Highest Recoveries Ever

    By Jaime L.M. Jones, Matt Bergs, Anna M. Schmitt

    Last week, DOJ released its annual report detailing FCA recoveries and new cases, which can be found here.  In the press release, accessible here, DOJ touts two records in fiscal…

  8. Original Source

    First Circuit Clarifies Application of Medicare’s “Reasonable and Necessary” Standard in FCA Cases Against Clinical Labs

    By Scott D. Stein, Joseph R. LoCascio, Anna M. Schmitt

    Earlier this week, the First Circuit in OMNI Healthcare held that “in FCA cases alleging Medicare fraud based on laboratory testing, generally a laboratory can rely on a doctor’s order…

  9. Original Source

    Court Refuses to Reduce $290 Million FCA Judgment, Finding Damages and Penalties Assessed To Be Constitutionality Appropriate

    By Jaime L.M. Jones, Matt Bergs, Mariya Denisko

    We have previously reported on two district court decisions from Minnesota and Texas analyzing FCA damages and penalties under the Eighth Amendment Excessive Fines Clause, with both courts finding the…

  10. Original Source

    DOJ Reaches $9.8 Million Settlement with Genetic Testing Company Illumina Inc. to Resolve FCA Allegations

    By Jaime L.M. Jones, Benjamin B. Correa, Monica Kofron

    DOJ announced that genetic testing company Illumina Inc. will pay $9.8 million to resolve allegations that it sold genomic sequencing systems with cybersecurity vulnerabilities to the various federal Departments and…